<DOC>
	<DOCNO>NCT02845999</DOCNO>
	<brief_summary>Gastrointestinal ( GI ) cancer account common cancer . Despite recent advance GI cancer treatment , 5-year overall survival rate patient remain unacceptable , except patient candidate metastasis surgical resection . Strategies lead decrease metastatic number size contribute improve probability undergo curative surgical procedure . Haploidentical Natural Killer ( NK ) cell persist expand vivo follow adoptive transfer may role treatment select malignancy , since failure recognize appropriate KIR ligand mismatch tumor cell trigger NK cell elimination target cell . NK also express activate Fc receptor mediate antibody-dependent cellular cytotoxicity ( ADCC ) production immune modulatory cytokine response antibody-coated target . Cetuximab , IgG1 chimeric monoclonal antibody colorectal cancer express EGFR ( epidermal growth factor receptor ) , improve overall survival progression-free survival preserve quality-of-life measure patient colorectal cancer treatment fail . In attempt improve outcome GI cancer , conduct phase I/II clinical trial assess NK cell base immunotherapy . Patients liver metastasis relate EGFR+ GI cancer , previously treat standard chemotherapy achieve complete response curative resection residual metastasis include phase I/II trial support French National Institute Cancer ( INCA , PHRC 2005 ) . This phase I/II study involve 22 patient . The main objective study demonstrate safety NK hepatic intraarterial infusion association cetuximab . Secondary objective include assessment clinical efficacity strategy .</brief_summary>
	<brief_title>Allogenic Immunotherapy Based Natural Killer ( NK ) Cell Adoptive Transfer Metastatic Gastrointestinal Carcinoma Treated With Cetuximab</brief_title>
	<detailed_description>Patients treat condition chemotherapy include 60 mg/kg intravenous cyclophosphamide , 25 mg/m2 intravenous fludarabine 5 consecutive day cetuximab . A lymphapheresis haploidentical relate donor perform T cell deplete . Allogenic NK cell adoptively transfer hepatic intraarterial infusion accord dose escalation protocol ( three dos least three patient per cohort ) define dose-limiting toxicity ( DLT ) . Then 10 patient receive recommend NK cell dose . Dose escalation protocol : 3.10^6 ; 8.10^6 12.10^6 cells/kg recipient body weight .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>metastatic gastrointestinal cancer ( colorectal , pancreas , small intestine , bile duct ) , gastrointestinal stromal tumor digestive neuroendocrine tumor . presence liver metastases Age &gt; 18 &lt; 65 ( male female ) ECOG performances status 0 1 EGFR expression confirm immunohistochemistry allogenic donor one KIR/MHC class I mismatch absence alternative treatment available evidence progressive disease write informed consent malignant secondary disease date back &lt; 2 year ( exception : situ carcinoma cervix uterus , adequately treat skin basal cell carcinoma ) hypersensitivity one treatment study history cardiac respiratory failure history autoimmune disease renal hepatic failure pregnancy lactation patient medical psychiatric condition disease would make patient inappropriate entry study . EBV serology negative recipient positive donor bilirubin great 1,5 time upper limit normal ASAT and/or alkaline phosphatase great 5 time upper limit normal presence liver metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>natural killer cell</keyword>
	<keyword>adoptive transfer</keyword>
	<keyword>allogenic immunotherapy</keyword>
	<keyword>gastrointestinal cancer EGFR+</keyword>
</DOC>